Table 2.
Pharmacokinetic properties of US FDA-approved GLP-1 receptor agonists
| Brand name | Generic name | Half-life | Volume of distribution | Elimination |
|---|---|---|---|---|
| Byetta28 | Exenatide | 2.4 hours | 28.3 L | Glomerular filtration |
| Bydureon29 | Exenatide XR | 2 weeks | 28.3 L | Glomerular filtration |
| Victoza3 | Liraglutide | 13 hours | 13 L | Urine and feces (metabolite) |
| Trulicity30 | Dulaglutide | 5 days | 9.3–33 L | – |
| Adlyxin31 | Lixisenatide | 1–3.5 hours | 100 L | Glomerular filtration |
| Ozempic32 | Semaglutide | 1 week | 12.5 L | Urine and feces |
Abbreviations: L, liters; T2DM, type 2 diabetes mellitus; FDA, Food and Drug Administration; GLP-1, glucagon-like peptide-1; XR, extended release.